In a post on the the IVI-sponsored Health Affairs blog series, Henry Grabowski and Richard Manning offer a rebuttal to a recent Health Affairs blog commentary by Nancy Yu, Zachary Helms, and Peter Bach on the subject of drug pricing. In their rebuttal, Grabowski and Manning caution that the premise of the earlier blog post — that U.S. price premiums could be substantially reduced without affecting research and development investments or having other adverse effects — is flawed and lacks basic economic principals necessary for sound health policy making.
Read the full article here.
About the Health Affairs/IVI Blog Series: Drugs and Medical Innovation — In partnership with Health Affairs, IVI is proud to sponsor the “Drugs and Medical Innovation” blog series. On an ongoing basis, articles in this series will explore topics such as value-based reimbursement, drug policy and pricing, balancing short-term access against long-term rates of innovation, and other relevant issues. Our goal is to create an open forum for sharing ideas and debating issues in these areas, extending the discussion to a broader audience.
